Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is supported by a durable Filspari franchise, with USPTO allowance for FSGS method-of-use patent coverage expected into October 2037 and a similar IgAN patent already granted into October 2037, easing a major exclusivity concern. Commercial execution is also strong, as 2Q26 FILSPARI revenue reached $141.1M with 2,012 new patient start forms, while nephrology survey data points to rising physician intent in both IgAN and FSGS. The transition to Bradley Campbell adds a seasoned rare-disease operator at a point when the company can expand beyond Filspari, and advancing pegtibatinase and civorebrutinib should help diversify the story further.

Travere Therapeutics is facing a negative fundamental setup because its $489.2 million cash, cash equivalents and marketable securities balance at the end of 1Q 2026 may still prove insufficient if commercialization or development costs rise faster than expected. The company may need to access capital markets, and any follow-on stock offering could dilute existing shareholders, while tighter market access would limit its ability to fund development and commercialization. In addition, delays, setbacks, or regulatory requests for additional data on Filspari or pegtibatinase could extend timelines, increase spend, and materially reduce sales potential and valuation.